Bach Julia, Lewis Nathaniel, Maggiora Kathy, Gillespie Alison J, Connell-Crowley Lisa
Drug Substance Development, Amgen Inc., 1201 Amgen Court West, Seattle, WA 98119, United States.
Drug Substance Development, Amgen Inc., 1201 Amgen Court West, Seattle, WA 98119, United States.
J Chromatogr A. 2015 Aug 28;1409:60-9. doi: 10.1016/j.chroma.2015.06.064. Epub 2015 Jul 2.
This work examines the binding of 15 different VH3 IgGs and their corresponding F(ab')2 fragments to two different protein A chromatography resins: MabSelect(®), which utilizes a recombinant protein A ligand, and MabSelect SuRe(®) (SuRe), which utilizes a tetrameric Z domain ligand. The results show that VH3 F(ab')2 fragments can exhibit a variety of binding behaviours for the two resins. Contrary to previously published data, a subset of these molecules show strong interaction with the Z domain of SuRe(®). Furthermore, the results show that sequence variability of residue 57 in the VH3 heavy chain CDR2 domain correlates with binding behaviour on MabSelect(®) and SuRe(®). Site-directed mutagenesis of this residue confers gain or loss of VH3 F(ab')2 binding to these resins in 3 mAbs, demonstrating that it plays a key role in both recombinant protein A and Z domain interaction. A fourth mAb with a longer CDR2 loop was not affected by mutation of residue 57, indicating that CDR2 domain length may alter the binding interface and lead to the involvement of other residues in protein A binding.
本研究考察了15种不同的VH3 IgG及其相应的F(ab')2片段与两种不同的蛋白A层析树脂的结合情况:一种是利用重组蛋白A配体的MabSelect(®),另一种是利用四聚体Z结构域配体的MabSelect SuRe(®)(SuRe)。结果表明,VH3 F(ab')2片段对这两种树脂可表现出多种结合行为。与先前发表的数据相反,这些分子中的一部分与SuRe(®)的Z结构域表现出强烈相互作用。此外,结果表明VH3重链CDR2结构域中第57位残基的序列变异性与在MabSelect(®)和SuRe(®)上的结合行为相关。对该残基进行定点诱变可导致3种单克隆抗体的VH3 F(ab')2与这些树脂的结合增加或减少,表明其在重组蛋白A和Z结构域相互作用中均起关键作用。一种具有较长CDR2环的第四种单克隆抗体不受第57位残基突变的影响,表明CDR2结构域长度可能改变结合界面并导致其他残基参与蛋白A结合。